Lead optimisation
Hit to lead
Assay Development
Therapeutic area
  • Cancer

Project Aim

To develop an ADC against anaplastic lymphoma kinase 1 (ALK) for the treatment of neuroblastoma


Exploits ALK as a tumour marker and is independent of its role in driving disease. Less likely to induce resistance than current therapies

Target Class

Receptor tyrosine kinase


Antibody drug conjugate

Current Status

Antibody generated and shown to internalise on ALK binding. Conjugation prior to in-vitro proof of concept and humanisation

Intellectual Property

Opportunity to create a protective IPR portfolio



Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities